Innovotech Inc. has announced its intention to obtain a stock quotation in the United States on the OTCQB Venture Market, an over-the-counter platform that will operate alongside the company's primary Canadian listing on the TSX Venture Exchange. This strategic move aims to enhance the company's visibility within the U.S. investment community and make its shares more accessible to both retail and institutional investors across the border. The OTCQB quotation is expected to increase trading liquidity for Innovotech's common shares without imposing significant additional compliance burdens.
As a foreign private issuer, the company will continue meeting its existing disclosure obligations through Canada's SEDAR+ system, which satisfies OTC market requirements under established foreign issuer exemptions. Companies seeking admission to the OTCQB must meet specific financial standards, maintain current reporting, and undergo annual verification and management certification processes. In conjunction with the OTCQB application, Innovotech will also seek eligibility with the Depository Trust Company, which would enable simplified electronic clearing and settlement of its shares for U.S.-based investors. This dual approach reflects the company's strategy to expand its investor base while maintaining operational efficiency.
Innovotech operates as a Canadian boutique contract research organization specializing in advanced laboratory services and proprietary technology commercialization. The company has established expertise in biofilm science and provides antimicrobial testing, pharmaceutical analysis, and industrial laboratory solutions. Its services include the widely-used MBEC Assay® kit for high-throughput antimicrobial and antibiotic testing, serving clients across multiple sectors through ISO-certified and GMP-accredited laboratories that meet regulatory standards including those of the U.S. Food and Drug Administration and Health Canada. More information about the company's services and technologies is available at https://www.innovotech.ca.
The company's forward-looking statements acknowledge potential risks including regulatory uncertainties, currency fluctuations, customer concentration, operating result variability, government policy changes, clinical trial costs, reliance on strategic relationships, intellectual property concerns, and litigation exposure. These factors could cause actual results to differ materially from expectations, though the company notes it will update forward-looking statements as required by applicable law. The OTCQB listing represents a calculated expansion strategy that could significantly broaden Innovotech's investor reach while leveraging existing regulatory frameworks to minimize administrative overhead.
